Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009867/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to acquire additional data on efficacy, safety, tolerability,
immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to
<16 years) participants with primary immunodeficiency disease (PIDD).
提供机构：
Vivli
创建时间：
2024-03-11
